Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas
Clin. transl. oncol. (Print)
; 12(7): 468-472, jul. 2010.
Artigo
em Inglês
| IBECS
| ID: ibc-124100
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Sarcomas are uncommon malignancies that represent more than 50 different tumor types. Surgery remains the mainstay of treating localised disease. Anthracycline and ifosfamide-based chemotherapy is an option for advanced disease; however, effective treatment of advanced soft tissue sarcoma remains a challenge. Advances in understanding the genetic nature of cancer have led to the development of new treatment options for sarcoma. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor with antiangiogenic properties and promising activity in the treatment of GIST refractory to imatinib, however in either soft tissue sarcoma, experience with sunitinib is under development in different clinical trials. In this review we offer the experience with this small molecular target in non-GIST sarcomas (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Pirróis
/
Sarcoma
/
Proteínas Tirosina Quinases
/
Inibidores de Proteínas Quinases
/
Indóis
/
Antineoplásicos
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2010
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital Universitario 12 de Octubre/Spain